Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Exclusively Distribute Two DxS Cancer Companion Tests

NEW YORK (GenomeWeb News) – Roche said Monday that it will distribute two cancer mutation tests for the UK molecular diagnostics company DxS.
 
DxS makes companion diagnostics that can be used by oncologists to aid in the prognosis and development of treatments for cancer patients based on specific gene mutations, Roche said.
 
Roche will distribute the TheraScreen K-RAS Mutation Test, which detects seven mutations found in many cancer types and is used in colorectal cancer cases, through a worldwide, exclusive agreement.
 
The second test involved in the agreement, the TheraScreen EGFR 29 Mutation Test, detects mutations that correlate with responsiveness to EGFR tyrosine kinase inhibitors. This test may be used to help doctors choose lung cancer patients who are most likely to respond to treatment with EGFR tyrosine kinase inhibitors.
 
Roche has agreed to distribute this test exclusively to all global markets except the US, Canada, Mexico, and Hong Kong. Both of the companion tests have received European CE mark certification.
 
Financial terms of the agreement were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more